NASDAQ:NAGE Niagen Bioscience (NAGE) Stock Price, News & Analysis $3.00 -0.02 (-0.50%) As of 11:16 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Niagen Bioscience Stock (NASDAQ:NAGE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Niagen Bioscience alerts:Sign Up Key Stats Today's Range$2.98▼$3.0250-Day Range$2.96▼$3.5352-Week Range$2.87▼$10.06Volume46,164 shsAverage Volume877,401 shsMarket Capitalization$238.52 millionP/E Ratio16.64Dividend YieldN/APrice Target$10.33Consensus RatingBuy Company Overview Niagen Bioscience, Inc. is a bioscience company focused on developing and commercializing products designed to support healthy aging and cellular energy metabolism. The company’s research centers on nicotinamide riboside (NR), a form of vitamin B3 and precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in numerous cellular processes. The company markets its proprietary NIAGEN branded NR ingredient to supplement manufacturers and sells consumer products under the Tru Niagen brand. Tru Niagen products are available in dietary supplement formulations intended to support NAD+ levels and cellular health. Niagen Bioscience also maintains intellectual property and conducts research related to NR and NAD+ biology. The company was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name as part of its focus on the NIAGEN platform. Its products are marketed through direct-to-consumer and commercial channels in the United States and internationally. The company is led by Chief Executive Officer Robert N. Fried.AI Generated. May Contain Errors. Read More Niagen Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreNAGE MarketRank™: Niagen Bioscience scored higher than 66% of companies evaluated by MarketBeat, and ranked 83rd out of 171 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingNiagen Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialNiagen Bioscience has a consensus price target of $10.33, representing about 245.0% upside from its current price of $3.00.Amount of Analyst CoverageNiagen Bioscience has only been the subject of 4 research reports in the past 90 days.Read more about Niagen Bioscience's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth7.69% Earnings GrowthEarnings for Niagen Bioscience are expected to grow by 7.69% in the coming year, from $0.13 to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Niagen Bioscience is 16.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Niagen Bioscience is 16.64, which means that it is trading at a more expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 14.08.Price to Book Value per Share RatioNiagen Bioscience has a P/B Ratio of 3.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.58% of the float of Niagen Bioscience has been sold short.Short Interest Ratio / Days to CoverNiagen Bioscience has a short interest ratio ("days to cover") of 11.29, which indicates bearish sentiment.Change versus previous monthShort interest in Niagen Bioscience has recently decreased by 3.84%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNiagen Bioscience does not currently pay a dividend.Dividend GrowthNiagen Bioscience does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.28 News SentimentNiagen Bioscience has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Niagen Bioscience this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for NAGE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Niagen Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders10.00% of the stock of Niagen Bioscience is held by insiders.Percentage Held by Institutions15.41% of the stock of Niagen Bioscience is held by institutions.Read more about Niagen Bioscience's insider trading history. Receive NAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Niagen Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAGE Stock News HeadlinesNiagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Recommendation of "Buy" from AnalystsSeptember 24 at 2:15 AM | americanbankingnews.comNewly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with ...September 21, 2026 | marketscreener.comMSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 25 at 1:00 AM | Altimetry (Ad)Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy OutcomesSeptember 21, 2026 | businesswire.comAnalysts Offer Insights on Consumer Goods Companies: Celsius Holdings (CELH) and Niagen Bioscience (NAGE)September 19, 2026 | theglobeandmail.comNiagen Bioscience, Inc. (NAGE)September 18, 2026 | finance.yahoo.comNiagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business GrowthSeptember 17, 2026 | businesswire.comNiagen Bioscience to Present at Canaccord Genuity’s Well SummitSeptember 10, 2026 | finance.yahoo.comSee More Headlines NAGE Stock Analysis - Frequently Asked Questions How have NAGE shares performed this year? Niagen Bioscience's stock was trading at $6.36 at the beginning of 2026. Since then, NAGE shares have decreased by 52.9% and is now trading at $2.9950. How were Niagen Bioscience's earnings last quarter? Niagen Bioscience, Inc. (NASDAQ:NAGE) posted its quarterly earnings data on Tuesday, August, 4th. The company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. The business earned $29.78 million during the quarter, compared to the consensus estimate of $29.95 million. Niagen Bioscience had a net margin of 12.39% and a trailing twelve-month return on equity of 17.95%. Who are Niagen Bioscience's major shareholders? Top institutional investors of Niagen Bioscience include Tieton Capital Management LLC (2.52%), Bank of New York Mellon Corp (0.25%), Tidal Investments LLC (0.16%) and Squarepoint Ops LLC (0.15%). Insiders that own company stock include Frank L Jaksch Jr, Brianna Gerber, Ozan Pamir and Kristin Patrick. View institutional ownership trends. How do I buy shares of Niagen Bioscience? Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/04/2026Today9/25/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (11m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NAGE's financial health is in the Red zone, according to TradeSmith. NAGE has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Staples Industry Personal Care Products Sub-IndustryPersonal Care Products Current SymbolNASDAQ:NAGE Previous SymbolNASDAQ:NAGE CIK1386570 Webwww.niagenbioscience.com Phone(310) 388-6706Fax949-419-0294Employees117Year FoundedN/APrice Target and Rating Average Price Target for Niagen Bioscience$10.33 High Price Target$11.00 Low Price Target$10.00 Potential Upside/Downside+246.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.18 Trailing P/E Ratio16.58 Forward P/E Ratio22.96 P/E GrowthN/ANet Income$17.38 million Net Margins12.39% Pretax Margin13.19% Return on Equity17.95% Return on Assets13.17% Debt Debt-to-Equity RatioN/A Current Ratio6.50 Quick Ratio5.13 Sales & Book Value Annual Sales$129.42 million Price / Sales1.84 Cash Flow$0.20 per share Price / Cash Flow15.24 Book Value$0.96 per share Price / Book3.11Miscellaneous Outstanding Shares79,640,000Free Float71,680,000Market Cap$237.73 million OptionableN/A Beta2.09 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:NAGE) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
